Charts

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $100.68 per unit.

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003,

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET. A live webcast of the presentation will be available on the Events page of the I

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose ...

— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary

CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD). The AAV-SLB101 caps

CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Leerink Partners Global Biopharma Conference – Miami, FL1x1 meetings on March 11, 2024Barclays 26th Annual Global Healthcare Conference – Miami, FLBo Cumbo, Solid’s President and Chief Executive Officer, will present on Wednesday, Mar

In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key ...

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock increased by 55.3% to $5.08 during Thursday's regular session. The market value of ...

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported ...

Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their ...

Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate. “Obtaining ODD status

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates ...

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Gainers NexImmune (NASDAQ:NEXI) shares rose 97.5% to $14.95 during Tuesday's regular session. The company's market cap stands at $15.8 ...

CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions.

CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:45 am PT. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking

Key Insights The considerable ownership by private equity firms in Solid Biosciences indicates that they collectively...

Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly ...

Gainers Exicure (NASDAQ:XCUR) stock increased by 63.9% to $0.66 during Friday's pre-market session. The market value of their ...

Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter. The company ...

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Gainers Exicure (NASDAQ:XCUR) stock rose 54.5% to $0.66 during Thursday's after-market session. The market value of their outstanding ...

Solid Biosciences Inc. (NASDAQ: SLDB) shares tradedhigher on Thursday. The company announced that it received Fast Track ...

Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly ...

– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy cand

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by click

Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. Dolby Laboratories ...

Gainers Altamira Therapeutics (NASDAQ:CYTO) stock increased by 222.5% to $0.32 during Friday's regular session. As of 12:31 EST, this ...

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways ...

Solid Biosciences Inc. (NASDAQ: SLDB) shares are trading higher Wednesday after the company announced that it has received FDA clearance ...

Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter ...

Gainers Chemomab Therapeutics (NASDAQ:CMMB) shares moved upwards by 65.6% to $1.01 during Wednesday's pre-market session. The market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

On Thursday, 369 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company ...

On Monday, 369 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows: Danaher (NYSE:DHR) ...

On Tuesday, 386 stocks made new 52-week lows. Interesting Points From Today's 52-Week Lows: Diageo (NYSE:DEO) was ...

Upgrades For Agile Therapeutics Inc (NASDAQ:AGRX), Maxim Group upgraded the previous rating of Hold to Buy. For the second quarter, ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19.

Friday's session saw 225 companies set new 52-week lows. Significant Points From Today's 52-Week ...

Earlier today,Biogen Inc(NASDAQ: BIIB) agreed to acquireReata Pharmaceuticals Inc(NASDAQ: RETA) for $172.50 per ...

Joe Lewis is accused by U.S. authorities of sharing secret stock tips with his private pilots, girlfriends and assistants for years

Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:40 AM. Here's what investors need to ...

Gainers Cosmos Holdings (NASDAQ:COSM) stock rose 45.1% to $0.48 during Thursday's pre-market session. The company's market cap stands ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to which shareholders of AavantiBio are expected to own approximately 15% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While some stocks to buy have performed surprisingly well recently, they remain relatively obscure, providing a contrarian opportunity. The post 7 Sizzling Stocks That Are Oblivious to the Manic Market appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.

Solid Biosciences Inc(NASDAQ: SLDB)presented additional datacharacterizing AAV-SLB101, a novel adeno-associated ...

Upgrades For Citi Trends Inc (NASDAQ:CTRN), Gordon Haskett upgraded the previous rating of Reduce to Hold. For the second quarter, ...

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Solid Biosciences Inc. (NASDAQ: SLDB) and AavantiBio, Inc. is fair to Solid shareholders.